# PHAROS (NCT03915951)

> An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: encorafenib plus binimetinib
- Indication: BRAF V600E-mutant metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03915951
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Non-small Cell Lung Cancer
- Interventions: encorafenib; binimetinib
- Enrollment: 98
- Primary outcome: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR)

## Indexed commentary on PHAROS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 30
- YouTube: 3
- Podcasts: 3
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pharos-nct03915951

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03915951", "email": "<work email>"}; the inbox owner confirms by the emailed link.